Remedent, Inc.
REMI · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23% | 78.1% | -14.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.6% | 65.7% | 58.2% | 54% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -48.9% | 10.4% | -4.4% | -11.5% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -86.4% | 10.9% | -15.9% | -28.4% |
| EPS | -0.011 | 0.002 | -0.002 | -0.003 |
| % Growth | -711.1% | 220% | 51.6% | – |
| EPS Diluted | -0.011 | 0.002 | -0.002 | -0.003 |
| Weighted Avg Shares Out | 20 | 20 | 20 | 20 |
| Weighted Avg Shares Out Dil | 20 | 20 | 20 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -80.5% | 17.6% | -16.3% | -16.7% |